Search Results - "Van Poznak, Catherine H."

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline by Yarom, Noam, Shapiro, Charles L, Peterson, Douglas E, Van Poznak, Catherine H, Bohlke, Kari, Ruggiero, Salvatore L, Migliorati, Cesar A, Khan, Aliya, Morrison, Archie, Anderson, Holly, Murphy, Barbara A, Alston-Johnson, Devena, Mendes, Rui Amaral, Beadle, Beth Michelle, Jensen, Siri Beier, Saunders, Deborah P

“…To provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer…”
Get full text

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline by Dhesy-Thind, Sukhbinder, Fletcher, Glenn G, Blanchette, Phillip S, Clemons, Mark J, Dillmon, Melissa S, Frank, Elizabeth S, Gandhi, Sonal, Gupta, Rasna, Mates, Mihaela, Moy, Beverly, Vandenberg, Ted, Van Poznak, Catherine H

“…Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer…”
Get full text

Activating ESR1 mutations in hormone-resistant metastatic breast cancer by Robinson, Dan R, Wu, Yi-Mi, Vats, Pankaj, Su, Fengyun, Lonigro, Robert J, Cao, Xuhong, Kalyana-Sundaram, Shanker, Wang, Rui, Ning, Yu, Hodges, Lynda, Gursky, Amy, Siddiqui, Javed, Tomlins, Scott A, Roychowdhury, Sameek, Pienta, Kenneth J, Kim, Scott Y, Roberts, J Scott, Rae, James M, Van Poznak, Catherine H, Hayes, Daniel F, Chugh, Rashmi, Kunju, Lakshmi P, Talpaz, Moshe, Schott, Anne F, Chinnaiyan, Arul M

“…Arul Chinnaiyan and colleagues report the results of prospective clinical sequencing of 11 estrogen receptor–positive metastatic breast cancers. They identify…”
Get full text

American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer by VAN POZNAK, Catherine H, TEMIN, Sarah, ZUCKERMAN, Dan S, VON ROENN, Jamie H, YEE, Gary C, JANJAN, Nora A, BARLOW, William E, BIERMANN, J. Sybil, BOSSERMAN, Linda D, GEOGHEGAN, Cindy, HILLNER, Bruce E, THERIAULT, Richard L

“…To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with…”
Get full text

NCCN Task Force Report: Bone Health In Cancer Care by Gralow, Julie R, Biermann, J Sybil, Farooki, Azeez, Fornier, Monica N, Gagel, Robert F, Kumar, Rashmi, Litsas, Georgia, McKay, Rana, Podoloff, Donald A, Srinivas, Sandy, Van Poznak, Catherine H

“…Bone health and maintenance of bone integrity are important components of comprehensive cancer care. Many patients with cancer are at risk for therapy-induced…”
Get more information

Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research by Khosla, Sundeep, Burr, David, Cauley, Jane, Dempster, David W, Ebeling, Peter R, Felsenberg, Dieter, Gagel, Robert F, Gilsanz, Vincente, Guise, Theresa, Koka, Sreenivas, McCauley, Laurie K, McGowan, Joan, McKee, Marc D, Mohla, Suresh, Pendrys, David G, Raisz, Lawrence G, Ruggiero, Salvatore L, Shafer, David M, Shum, Lillian, Silverman, Stuart L, Van Poznak, Catherine H, Watts, Nelson, Woo, Sook‐Bin, Shane, Elizabeth

“…ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a…”
Get full text

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 by Paoletti, Costanza, Li, Yufeng, Muñiz, Maria C, Kidwell, Kelley M, Aung, Kimberly, Thomas, Dafydd G, Brown, Martha E, Abramson, Vandana G, Irvin, Jr, William J, Lin, Nancy U, Liu, Minetta C, Nanda, Rita, Nangia, Julie R, Storniolo, Anna M, Traina, Tiffany A, Vaklavas, Christos, Van Poznak, Catherine H, Wolff, Antonio C, Forero-Torres, Andres, Hayes, Daniel F

“…Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in…”
Get full text

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover by Oesterreich, Steffi, Henry, N. Lynn, Kidwell, Kelley M., Van Poznak, Catherine H., Skaar, Todd C., Dantzer, Jessica, Li, Lang, Hangartner, Thomas N., Peacock, Munro, Nguyen, Anne T., Rae, James M., Desta, Zeruesenay, Philips, Santosh, Storniolo, Anna M., Stearns, Vered, Hayes, Daniel F., Flockhart, David A.

“…Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI…”
Get full text

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases by Freedman, Rachel A, Gelman, Rebecca S, Anders, Carey K, Melisko, Michelle E, Parsons, Heather A, Cropp, Anne M, Silvestri, Kelly, Cotter, Christine M, Componeschi, Kathryn P, Marte, Juan M, Connolly, Roisin M, Moy, Beverly, Van Poznak, Catherine H, Blackwell, Kimberly L, Puhalla, Shannon L, Jankowitz, Rachel C, Smith, Karen L, Ibrahim, Nuhad, Moynihan, Timothy J, O'Sullivan, Ciara C, Nangia, Julie, Niravath, Polly, Tung, Nadine, Pohlmann, Paula R, Burns, Robyn, Rimawi, Mothaffar F, Krop, Ian E, Wolff, Antonio C, Winer, Eric P, Lin, Nancy U

“…Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported…”
Get full text

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update by Eisen, Andrea, Somerfield, Mark R, Accordino, Melissa K, Blanchette, Phillip S, Clemons, Mark J, Dhesy-Thind, Sukhbinder, Dillmon, Melissa S, D'Oronzo, Stella, Fletcher, Glenn G, Frank, Elizabeth S, Hallmeyer, Sigrun, Makhoul, Issam, Moy, Beverly, Thawer, Alia, Wu, Joy Y, Van Poznak, Catherine H

“…To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in…”
Get full text

MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw by Yarom, Noam, Van Poznak, Catherine H., Epstein, Joel B., Ottaviani, Giulia, Matsuda, Yuhei, Migliorati, Cesar, Elad, Sharon

“…Purpose A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for…”
Get full text

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307 by Gralow, Julie R, Barlow, William E, Paterson, Alexander H G, M'iao, Jieling L, Lew, Danika L, Stopeck, Alison T, Hayes, Daniel F, Hershman, Dawn L, Schubert, Mark M, Clemons, Mark, Van Poznak, Catherine H, Dees, Elizabeth C, Ingle, James N, Falkson, Carla I, Elias, Anthony D, Messino, Michael J, Margolis, Jeffrey H, Dakhil, Shaker R, Chew, Helen K, Dammann, Kim Z, Abrams, Jeffrey S, Livingston, Robert B, Hortobagyi, Gabriel N

“…Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines…”
Get full text

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases by Freedman, Rachel A, Gelman, Rebecca S, Wefel, Jeffrey S, Melisko, Michelle E, Hess, Kenneth R, Connolly, Roisin M, Van Poznak, Catherine H, Niravath, Polly A, Puhalla, Shannon L, Ibrahim, Nuhad, Blackwell, Kimberly L, Moy, Beverly, Herold, Christina, Liu, Minetta C, Lowe, Alarice, Agar, Nathalie Y R, Ryabin, Nicole, Farooq, Sarah, Lawler, Elizabeth, Rimawi, Mothaffar F, Krop, Ian E, Wolff, Antonio C, Winer, Eric P, Lin, Nancy U

“…Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the CNS are limited. Neratinib is an…”
Get full text

Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials by Rugo, Hope S., Van Poznak, Catherine H., Neven, Patrick, Danielewicz, Iwona, Lee, Soo Chin, Campone, Mario, Chik, Jeannie Y. K., Vega Alonso, Estela, Naume, Bjørn, Brain, Etienne, Siegel, Jonathan M., Li, Rui, Uema, Deise, Wagner, Volker J., Coleman, Robert E.

“…Background Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone…”
Get full text

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 by King, Tari A, Lyman, Jaclyn P, Gonen, Mithat, Voci, Amy, De Brot, Marina, Boafo, Camilla, Sing, Amy Pratt, Hwang, E Shelley, Alvarado, Michael D, Liu, Minetta C, Boughey, Judy C, McGuire, Kandace P, Van Poznak, Catherine H, Jacobs, Lisa K, Meszoely, Ingrid M, Krontiras, Helen, Babiera, Gildy V, Norton, Larry, Morrow, Monica, Hudis, Clifford A

“…The objective of this study was to determine whether the 21-gene Recurrence Score (RS) provides clinically meaningful information in patients with de novo…”
Get full text

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer by Forero-Torres, Andres, Varley, Katherine E, Abramson, Vandana G, Li, Yufeng, Vaklavas, Christos, Lin, Nancy U, Liu, Minetta C, Rugo, Hope S, Nanda, Rita, Storniolo, Anna M, Traina, Tiffany A, Patil, Sujata, Van Poznak, Catherine H, Nangia, Julie R, Irvin, Jr, William J, Krontiras, Helen, De Los Santos, Jennifer F, Haluska, Paul, Grizzle, William, Myers, Richard M, Wolff, Antonio C

“…Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5(+) human tumor cells without crosslinking. TIG has strong in vitro/in vivo…”
Get full text

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer by Van Poznak, Catherine H, Unger, Joseph M, Darke, Amy K, Moinpour, Carol, Bagramian, Robert A, Schubert, Mark M, Hansen, Lisa Kathryn, Floyd, Justin D, Dakhil, Shaker R, Lew, Danika L, Wade, 3rd, James Lloyd, Fisch, Michael J, Henry, N Lynn, Hershman, Dawn L, Gralow, Julie

“…Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence…”
Get more information

Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer by Barton, Debra L., Brooks, Trevor M., Cieslak, Alison, Elkins, Gary R., Clark, Patricia M., Baydoun, Mohamad, Smith, Asa B., Van Poznak, Catherine H.

“…Background Sexual dysfunction, fueled by body image stress, is prevalent in women with a history of breast or gynecologic cancer. Preliminary data support that…”
Get full text

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622 by Schott, Anne F., Barlow, William E., Van Poznak, Catherine H., Hayes, Daniel F., Moinpour, Carol M., Lew, Danika L., Dy, Philip A., Keller, Evan T., Keller, Jill M., Hortobagyi, Gabriel N.

“…Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple…”
Get full text

Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis by Taichman, L. Susan, Van Poznak, Catherine H., Inglehart, Marita R.

“…Introduction Aromatase inhibitors (AIs) are a well-established component of adjuvant therapy in postmenopausal women with hormone receptor (HR) + early stage…”
Get full text